PPARγ synthetic agonists include members of the thiazolidinedione (TZD) class, such as the total agonists rosiglitazone and pioglitazone, which are widely applied in the treatment of T2DM due to their capability to enhance the sensitivity of target tissues to insulin and improve glucose metabolism. Here, PPARG is linked to type 2 diabetes mellitus.